Notice bibliographique
Résumé
Molecular Oncology is now entering into its fifth year of existence. Gone are the early days where the journal struggled to establish itself while finding the best possible way to implement the vision underlying its foundation. Molecular Oncology aims to provide the scientific community with a platform where scientists can show-case personal opinions as well as outreaching their original research to other scientists. The journal intends to serve readers not only by publishing state-of-the-art research, but also by providing a coherent body of reviews, often combined into thematic issues, planned to broadly and comprehensively address timely topics. We offer this topical content at no charge, either to authors or readers. Molecular Oncology also aims at influencing the political agenda in translational cancer research by promoting current and near-future political news and debate. In order to ensure that our authors enjoy increased visibility we have frequent campaigns to highlight specific aspects of Molecular Oncology. Not only do we reach out by e-mail, but also have made concerted efforts to have personal contact with delegates encountered by at various cancer related conferences. Judging from the performance indicators that can sensibly be used to evaluate a journal, we can proudly affirm that Molecular Oncology is thriving. We have received our first Journal Citations Reports impact factor (Thomson Reuters) and are now indexed in all major scientific bibliographic databases, such as PubMed and Scopus. In addition, all other available indicators point towards continued growth in the journal's standing – the inflow of manuscripts and the number of downloads have increased substantially in the last months. We are also happy to note that Molecular Oncology's readership is on the rise. As the field of translational cancer research matures, the number of related research areas develops at an ever-growing pace and with it the number of researchers working in the various fields across the cancer continuum. To keep abreast of these new developments, particularly in the area of personalized cancer medicine, we have appointed two Senior Associated Editors, Anne-Lise Børresen-Dale (Oslo, Norway) and Richard Schilsky (Chicago, USA), who will provide advice on new areas to be covered by the journal and help to further establish Molecular Oncology within this competitive field. Moreover, we have appointed eleven new members to the Editorial Board – Ruedi Aebersold (Zurich, Switzerland), René Bernards (Amsterdam, The Netherlands), Stephen Baylin (Baltimore, USA), Hedvig Hricak, (New York, USA), Guido Kroemer (Paris, France), Ole C. Lingjaerde (Oslo, Norway), Tak W. Mak (Toronto, Canada), Elaine R. Mardis (St Louis, USA), Martine Piccart (Brussels, Belgium), Jorge S. Reis-Filho (London, UK), and Huanming Yang (Beijing, China) – whose joint expertise, together with that of our existing extensive network of collaborators will help guide the future development of the journal. We would like to take this opportunity to thank the members of the Editorial Board who are retiring this year for their commitment to the journal and for their invaluable assistance during our formative years. Finally, I would like to thank the readers for their ongoing support and to take this opportunity to invite you to submit research articles to Molecular Oncology. Looking forward to hearing from you soon and hoping to welcome you as one of our authors.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,007 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».